Management and Outcomes of ANCA-Associated Vasculitis at a Tertiary Healthcare Facility

Table 3

Summary of induction and maintenance treatment.

Therapy	Induction, % (n = 36)	Maintenance, % (n = 36)	Relapse induction, % (n = 7)	Relapse maintenance, % (n = 7)
Cyclophosphamide	66.7 (24)	0 (0)	0 (0)	0 (0)
Rituximab	19.4 (7)	16.7 (6)	85.7 (6)	28.6 (2)
Cyclophosphamide and rituximab	2.8 (1)	0 (0)	0 (0)	0 (0)
Azathioprine	11.1 (4)	61.1 (22)	0 (0)	57.1 (4)
Corticosteroids alone	0 (0)	16.7 (6)^a	14.3 (1)	14.3 (1)
Plasmapheresis	27.8 (10)	0 (0)	0 (0)	0 (0)
Mycophenolate mofetil	0 (0)	2.8 (1)	0 (0)	0 (0)
No treatment	0 (0)	2.8 (1)^b	0 (0)	0 (0)

^aDue to the commencement of HD or death in 4 (66.7%) of the patients, no information is available on 2 (33.3%) patients. ^bNot given further immunosuppression due to bowel perforation following cyclophosphamide. However, they remained clinically stable, with no worsening renal function.